Degarelix is a synthetic decapeptide and a potent gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used as an active pharmaceutical ingredient (API) in the treatment of advanced hormone-sensitive prostate cancer. By competitively binding to and blocking GnRH receptors in the pituitary gland, Degarelix rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a profound and sustained reduction in serum testosterone levels without the initial testosterone surge associated with GnRH agonists. This mechanism helps inhibit the growth of androgen-dependent prostate cancer cells. Degarelix is supplied as a sterile powder for reconstitution and subcutaneous injection in clinical formulations. It is a specialty pharmaceutical chemical with high purity requirements for therapeutic applications. Regular monitoring of hormone levels and potential side effects is recommended in therapeutic use.